Tryptamine Therapeutics has announced the dosing of the first subject in a clinical trial of TRP-8803, an intravenously (IV)-infused psilocin, in Adelaide, South Australia.

The first participant received TRP-8803 for approximately 140 minutes and completed the treatment without any issues. Following a post-dosing follow-up, the participant was safely discharged.

Dubbed the Healthy Human Volunteer Study, the trial is being conducted by CMAX Clinical Research, aiming to refine dosing and infusion rates for precise blood levels of psilocin as a psychedelic treatment.

It seeks to optimise the pharmacokinetics profile of TRP-8803 in up to 12 participants.

The goal is to establish the safety of TRP-8803 in humans, which will inform the Phase IIa patient study pipeline.

The study will also prepare for additional clinical trials targeting specific need states.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the potential benefits of IV-infused psilocin solution include faster onset, more precise control of the psychedelic experience, and a shorter duration of the intervention.

A lead programme of Tryp, TRP-8803 is set to address several limitations of oral psilocybin therapy.

The company plans to continue the trial with additional participants and expects to receive interim results by the third quarter of this year.

Positive outcomes from this study could significantly advance Tryp’s clinical trial pipeline across various conditions.

Tryp CEO Jason Carroll said: “Pleasingly, the maiden participant was delivered the infusion safely and was discharged on treatment conclusion, which provides management with confidence of TRP-8803 and the completion of this Healthy Human Volunteer Study.

“The trial, which being undertaken alongside CMAX is an incredibly important initiative for Tryp, as it will provide us with data highlighting TRP-8803’s safety in humans at escalating doses. This will form the basis of the company’s clinical trial pipeline into other indications and ultimately our regulatory engagement.”